Gyre, Cullgen Merge In $300M All-Stock Deal
By Jade Martinez-Pogue · March 2, 2026, 4:42 PM EST
Commercial-stage biopharmaceutical company Gyre Therapeutics Inc. on Monday announced plans to acquire clinical-stage biopharmaceutical company Cullgen Inc. in an all-stock deal valued at roughly $300 million....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login